Skip to main content
SpringerLink
Log in

Evaluation of the F2R IVS-14A/T PAR1 polymorphism with subsequent cardiovascular events and bleeding in patients who have undergone percutaneous coronary intervention

  • Published:
Journal of Thrombosis and Thrombolysis Aims and scope Submit manuscript

Abstract

Abnormal platelet reactivity is associated with recurrent ischemia and bleeding following percutaneous coronary intervention (PCI). Protease-activated receptor-1 (PAR1), encoded by F2R, is a high affinity thrombin receptor on platelets and the target of the antiplatelet drug vorapaxar. The intronic single nucleotide polymorphism F2R IVS-14 A/T affects PAR1 receptor density and function. We hypothesized that carriers of the T allele, who have been shown to have decreased platelet reactivity, would be at lower risk for thrombotic events, but higher risk for bleeding following PCI. Using BioVU, the Vanderbilt DNA repository linked to the electronic medical record, we studied 660 patients who underwent PCI for unstable or stable coronary artery disease. Primary outcome measures were major adverse cardiovascular events (MACE, composite of revascularization, MI, stroke, death) and bleeding (assessed by Bleeding Academic Research Consortium scale) over 24 months. The minor allele (T) frequency was 14.8 %. There were no genotypic differences in the frequency of MACE (33.7, 28.8, and 31.6 % for A/A, A/T, and T/T respectively, P = 0.50) or bleeding (15.7, 14.7, and 18.8 % for A/A, A/T, and T/T respectively, P = 0.90). In a Cox regression model, fully adjusted for age, race, sex, BMI, and smoking status, carrying a T allele was not associated with MACE (HR 1.19, 95 % CI 0.89–1.59, P = 0.23) or bleeding (HR 0.73, 95 % CI 0.37–1.4, P = 0.34). In conclusion, in our population, F2R IVS-14 PAR1 variability does not affect risk of MACE or bleeding following PCI.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Tantry US, Bonello L, Aradi D et al (2013) Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol 62:2261–2273

    Article  CAS  PubMed  Google Scholar 

  2. Trenk D, Hochholzer W, Fromm MF et al (2008) Cytochrome P450 2C19 681G > A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J Am Coll Cardiol 51:1925–1934

    Article  CAS  PubMed  Google Scholar 

  3. Harmsze A, van Werkum JW, Bouman HJ et al (2010) Besides CYP2C19*2, the variant allele CYP2C9*3 is associated with higher on-clopidogrel platelet reactivity in patients on dual antiplatelet therapy undergoing elective coronary stent implantation. Pharmacogenet Genomics 20:18–25

    Article  CAS  PubMed  Google Scholar 

  4. Simon T, Verstuyft C, Mary-Krause M et al (2009) Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 360:363–375

    Article  CAS  PubMed  Google Scholar 

  5. Collet JP, Cuisset T, Range G et al (2012) Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med 367:2100–2109

    Article  CAS  PubMed  Google Scholar 

  6. Bray PF (2007) Platelet hyperreactivity: predictive and intrinsic properties. Hematol Oncol Clin North Am 21:633–645, v–vi

  7. Coughlin SR (2005) Protease-activated receptors in hemostasis, thrombosis and vascular biology. J Thromb Haemost 3:1800–1814

    Article  CAS  PubMed  Google Scholar 

  8. Leger AJ, Covic L, Kuliopulos A (2006) Protease-activated receptors in cardiovascular diseases. Circulation 114:1070–1077

    Article  CAS  PubMed  Google Scholar 

  9. Lasne D, Krenn M, Pingault V et al (1997) Interdonor variability of platelet response to thrombin receptor activation: influence of PlA2 polymorphism. Br J Haematol 99:801–807

    Article  CAS  PubMed  Google Scholar 

  10. Dupont A, Fontana P, Bachelot-Loza C et al (2003) An intronic polymorphism in the PAR-1 gene is associated with platelet receptor density and the response to SFLLRN. Blood 101:1833–1840

    Article  CAS  PubMed  Google Scholar 

  11. Smith SM, Judge HM, Peters G et al (2005) PAR-1 genotype influences platelet aggregation and procoagulant responses in patients with coronary artery disease prior to and during clopidogrel therapy. Platelets 16:340–345

    Article  CAS  PubMed  Google Scholar 

  12. Sibbing D, Schulz S, Braun S et al (2010) Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement. J Thromb Haemost 8:250–256

    Article  CAS  PubMed  Google Scholar 

  13. Cuisset T, Cayla G, Frere C et al (2009) Predictive value of post-treatment platelet reactivity for occurrence of post-discharge bleeding after non-ST elevation acute coronary syndrome. Shifting from antiplatelet resistance to bleeding risk assessment? EuroIntervention 5:325–329

    Article  PubMed  Google Scholar 

  14. Campo G, Parrinello G, Ferraresi P et al (2011) Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome. J Am Coll Cardiol 57:2474–2483

    Article  CAS  PubMed  Google Scholar 

  15. Parodi G, Bellandi B, Venditti F et al (2012) Residual platelet reactivity, bleedings, and adherence to treatment in patients having coronary stent implantation treated with prasugrel. Am J Cardiol 109:214–218

    Article  CAS  PubMed  Google Scholar 

  16. Delaney JT, Ramirez AH, Bowton E et al (2012) Predicting clopidogrel response using DNA samples linked to an electronic health record. Clin Pharmacol Ther 91:257–263

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Cunningham A, Stein CM, Chung CP, Daugherty JR, Smalley WE, Ray WA (2011) An automated database case definition for serious bleeding related to oral anticoagulant use. Pharmacoepidemiol Drug Saf 20:560–566

    Article  PubMed  PubMed Central  Google Scholar 

  18. Mehran R, Rao SV, Bhatt DL et al (2011) Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation 123:2736–2747

    Article  PubMed  Google Scholar 

  19. Rao SV, Dai D, Subherwal S et al (2012) Association between periprocedural bleeding and long-term outcomes following percutaneous coronary intervention in older patients. JACC Cardiovasc Interv 5:958–965

    Article  PubMed  PubMed Central  Google Scholar 

  20. Ndrepepa G, Schuster T, Hadamitzky M et al (2012) Validation of the Bleeding Academic Research Consortium definition of bleeding in patients with coronary artery disease undergoing percutaneous coronary intervention. Circulation 125:1424–1431

    Article  PubMed  Google Scholar 

  21. Hulot JS, Bura A, Villard E et al (2006) Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 108:2244–2247

    Article  CAS  PubMed  Google Scholar 

  22. Mega JL, Close SL, Wiviott SD et al (2009) Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 360:354–362

    Article  CAS  PubMed  Google Scholar 

  23. Shuldiner AR, O’Connell JR, Bliden KP et al (2009) Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 302:849–857

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Stone GW, Witzenbichler B, Weisz G et al (2013) Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. Lancet 382:614–623

    Article  PubMed  Google Scholar 

  25. Frelinger AL 3rd, Bhatt DL, Lee RD et al (2013) Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in platelet function. J Am Coll Cardiol 61:872–879

    Article  CAS  PubMed  Google Scholar 

  26. Price MJ, Carfson AR, Murray SS et al (2012) First pharmacogenomic analysis using whole exome sequencing to identify novel genetic determinants of clopidogrel response variability: results of the Genotype Information and Functional Testing (GIFT) Exome Study. J Am Coll Cardiol 59:E9

    Article  Google Scholar 

  27. Bhatt DL (2009) Prasugrel in clinical practice. N Engl J Med 361:940–942

    Article  CAS  PubMed  Google Scholar 

  28. Menown IB (2011) Aspirin, P2Y12 blockers, cilostazol, PAR-1 blockers and emerging antiplatelet therapies: can biomarkers guide clinical development and practice? Biomark Med 5:1–3

    Article  CAS  PubMed  Google Scholar 

  29. Chhatriwalla AK, Amin AP, Kennedy KF et al (2013) Association between bleeding events and in-hospital mortality after percutaneous coronary intervention. JAMA 309:1022–1029

    Article  CAS  PubMed  Google Scholar 

  30. Price MJ, Berger PB, Teirstein PS et al (2011) Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 305:1097–1105

    Article  CAS  PubMed  Google Scholar 

  31. Storey RF, Kotha J, Smyth SS et al (2014) Effects of vorapaxar on platelet reactivity and biomarker expression in non-ST-elevation acute coronary syndromes. The TRACER Pharmacodynamic Substudy. Thromb Haemost 111:883–891

    Article  CAS  PubMed  Google Scholar 

  32. Cleator JH, Duvernay MT, Holinstat M et al (2014) Racial differences in resistance to P2Y12 receptor antagonists in type 2 diabetic subjects. J Pharmacol Exp Ther 351:33–43

    Article  PubMed  PubMed Central  Google Scholar 

  33. Behan MW, Fox SC, Heptinstall S, Storey RF (2005) Inhibitory effects of P2Y12 receptor antagonists on TRAP-induced platelet aggregation, procoagulant activity, microparticle formation and intracellular calcium responses in patients with acute coronary syndromes. Platelets 16:73–80

    Article  CAS  PubMed  Google Scholar 

  34. Tricoci P, Huang Z, Held C et al (2012) Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med 366:20–33

    Article  CAS  PubMed  Google Scholar 

  35. Morrow DA, Braunwald E, Bonaca MP et al (2012) Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med 366:1404–1413

    Article  CAS  PubMed  Google Scholar 

  36. Scirica BM, Bonaca MP, Braunwald E et al (2012) Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2 degrees P-TIMI 50 trial. Lancet 380:1317–1324

    Article  CAS  PubMed  Google Scholar 

  37. Cavender MA, Scirica BM, Bonaca MP et al (2015) Vorapaxar in patients with diabetes mellitus and previous myocardial infarction: findings from the thrombin receptor antagonist in secondary prevention of atherothrombotic ischemic events-TIMI 50 trial. Circulation 131:1047–1053

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Bonaca MP, Scirica BM, Braunwald E et al (2014) Coronary stent thrombosis with vorapaxar versus placebo: results from the TRA 2 degrees P-TIMI 50 trial. J Am Coll Cardiol 64:2309–2317

    Article  CAS  PubMed  Google Scholar 

  39. Kawai VK, Cunningham A, Vear SI et al (2014) Genotype and risk of major bleeding during warfarin treatment. Pharmacogenomics 15:1973–1983

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Cardiovascular Medicine, Vanderbilt University, Nashville, TN, USA

    Eitan A. Friedman, Luisa Texeira, Jessica Delaney, Donald R. Lynch Jr., Ehab Kasasbeh, Dan M. Roden & John H. Cleator

  2. Department of Pharmacology, Vanderbilt University, Nashville, TN, USA

    Heidi E. Hamm, Dan M. Roden & John H. Cleator

  3. Division of Clinical Pharmacology, Vanderbilt University, Nashville, TN, USA

    Jessica Delaney, Peter E. Weeke & Dan M. Roden

  4. Department of Biomedical Informatics, Vanderbilt University, Nashville, TN, USA

    Josh C. Denny

  5. Department of Biostatistics, Vanderbilt University, Nashville, TN, USA

    Yanna Song & Frank E. Harrell Jr.

  6. Vanderbilt Heart and Vascular Institute, 2220 Pierce Avenue, 383 PRB, Nashville, TN, 37232-6300, USA

    Dan M. Roden & John H. Cleator

Authors
  1. Eitan A. Friedman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Luisa Texeira
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jessica Delaney
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Peter E. Weeke
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Donald R. Lynch Jr.
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ehab Kasasbeh
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yanna Song
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Frank E. Harrell Jr.
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Josh C. Denny
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Heidi E. Hamm
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Dan M. Roden
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. John H. Cleator
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to John H. Cleator.

Additional information

Work supported by Vanderbilt Institute for Clinical and Translational Research Award to JHC.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Friedman, E.A., Texeira, L., Delaney, J. et al. Evaluation of the F2R IVS-14A/T PAR1 polymorphism with subsequent cardiovascular events and bleeding in patients who have undergone percutaneous coronary intervention. J Thromb Thrombolysis 41, 656–662 (2016). https://doi.org/10.1007/s11239-015-1285-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11239-015-1285-4

Keywords

Search

Navigation